• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    2/14/24 4:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    SC 13D/A 1 tm245508d1_sc13da.htm SC 13D/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         
      SCHEDULE 13D  

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Vor Biopharma Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    929033108

    (CUSIP Number)

     

    Paul A. Stone

    Chief Legal Officer

    5AM Venture Management, LLC

    501 2nd Street, Suite 350

    San Francisco, CA 94107

    (415) 993-8565

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    February 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    5AM Ventures VI, L.P.
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    WC
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     4,595,089 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    4,595,089 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
     4,595,089 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     6.8% (3)
      14. Type of Reporting Person (See Instructions)
    PN
               

    (1)This Schedule 13D is filed by 5AM Ventures VI, L.P. (“5AM VI”), 5AM Partners VI, LLC (“5AM Partners VI”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Dr. Parmar”), with 5AM VI, 5AM Partners VI, 5AM Opportunities, 5AM Opportunities GP and Schwab, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)These shares are held by 5AM VI. Schwab and Dr. Parmar, as Managing Members of 5AM Partners VI, share voting and investment authority over the shares held by 5AM VI.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2023.

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    5AM Partners VI, LLC
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    AF
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     4,595,089 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    4,595,089 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
     4,595,089 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     6.8% (3)
      14. Type of Reporting Person (See Instructions)
    OO
               

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes 4,595,089 shares held by 5AM VI. Schwab and Dr. Parmar, as Managing Members of 5AM Partners VI, share voting and investment authority over the shares held by 5AM VI.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    5AM Opportunities I, L.P.
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    WC
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     1,766,634 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    1,766,634 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,766,634 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     2.6% (3)
      14. Type of Reporting Person (See Instructions)
    PN
               

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)These shares are held by 5AM Opportunities. Schwab and Dr. Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    5AM Opportunities I (GP), LLC
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    AF
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     1,766,634 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    1,766,634 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
     1,766,634 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     2.6% (3)
      14. Type of Reporting Person (See Instructions)
    OO
               

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes 1,766,634 shares held by 5AM Opportunities. Schwab and Dr. Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    Andrew J. Schwab
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    AF
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     6,361,723 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    6,361,723 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
     6,361,723 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     9.4% (3)
      14. Type of Reporting Person (See Instructions)
    IN
               

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes (i) 4,595,089 shares held by 5AM VI; and (ii) 1,766,634 shares held by 5AM Opportunities. Schwab and Dr. Parmar, as Managing Members of 5AM Partners VI, share voting and investment authority over the shares held by 5AM VI. Schwab and Dr. Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

     

     

     

    CUSIP No.   929033108
      1. Names of Reporting Persons
    Dr. Kush Parmar
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  x (1)
      3. SEC Use Only
      4. Source of Funds (See Instructions)
    AF
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6. Citizenship or Place of Organization
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
     6,361,723 shares of Common Stock (2)
    9. Sole Dispositive Power
     0
    10. Shared Dispositive Power
    6,361,723 shares of Common Stock (2)
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
     6,361,723 shares of Common Stock (2)
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13. Percent of Class Represented by Amount in Row (11)
     9.4% (3)
      14. Type of Reporting Person (See Instructions)
    IN
               

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes (i) 4,595,089 shares held by 5AM VI; and (ii) 1,766,634 shares held by 5AM Opportunities. Schwab and Dr. Parmar, as Managing Members of 5AM Partners VI, share voting and investment authority over the shares held by 5AM VI. Schwab and Dr. Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

     

     

     

    Explanatory Note:      This Amendment No. 1 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on February 19, 2021 (the “Original Schedule 13D”) filed on behalf of 5AM Ventures VI, L.P. (“5AM VI”), 5AM Partners VI, LLC (“5AM Partners VI”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Dr. Parmar” and, with 5AM Partners VI, 5AM VI, 5AM Opportunities, 5AM Opportunities GP and Schwab, collectively, the “Reporting Persons”), relates to the Common Stock of Vor Biopharma Inc., a Delaware corporation (the “Issuer” or “Vor”). This Amendment to the Original Schedule 13D is being filed solely to update the benefical ownership percentages of the Reporting Persons resulting from an increase in the totalnumber of shares of Common Stock outstanding and not due to any transaction by the Reporting Persons.

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Original Schedule 13D is hereby amended and restated as follows:

     

    (a) – (b).       The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of February 14, 2024:

     

    Reporting Persons  Shares Held
    Directly
       Sole Voting
    Power
       Shared
    Voting
    Power(1)
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power (1)
       Beneficial
    Ownership
       Percentage
    of Class (3)
     
    5AM VI   4,595,089    0    4,595,089    0    4,595,089    4,595,089    6.8%
    5AM Partners VI (1)   0    0    4,595,089    0    4,595,089    4,595,089    6.8%
    5AM Opportunities   1,766,634    0    1,766,634    0    1,766,634    1,766,634    2.6%
    5AM Opportunities GP (2)   0    0    1,766,634    0    1,766,634    1,766,634    2.6%
    Schwab (1) (2)   0    0    6,361,723    0    6,361,723    6,361,723    9.4%
    Dr. Parmar (1) (2)   0    0    6,361,723    0    6,361,723    6,361,723    9.4%

     

    (1)Includes 4,595,089 shares of Common Stock held by 5AM VI. Schwab and Dr. Parmar, as Managing Members of 5AM Partners VI, share voting and investment authority over the shares held by 5AM VI.

     

    (2)Includes 1,766,634 shares of Common Stock held by 5AM Opportunities. Schwab and Dr. Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

     

    (3)This percentage is calculated based upon 67,805,687 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023.

     

    (c)Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Not applicable.

     

    Item 7.Material to be Filed as Exhibits

     

    A.Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (incorporated by reference to the Original Schedule 13D, filed on February 19, 2021).

     

    B.Amended and Restated Investors’ Rights Agreement, dated June 30, 2020 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-252175), filed with the SEC on February 3, 2021).

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    5AM Ventures VI, L.P.   5AM Opportunities I, L.P.
         
    By: 5AM Partners VI, LLC   By: 5AM Opportunities I (GP), LLC
    its General Partner     its General Partner  
         
    By: /s/ Andrew J. Schwab   By: /s/ Andrew J. Schwab  
    Name: Andrew J. Schwab   Name: Andrew J. Schwab  
    Title: Managing Member   Title: Managing Member  
         
    5AM Partners VI, LLC     5AM Opportunities I (GP), LLC  
         
    By: /s/ Andrew J. Schwab   By: /s/ Andrew J. Schwab  
    Name: Andrew J. Schwab     Name: Andrew J. Schwab  
    Title: Managing Member     Title: Managing Member  
         
      /s/ Andrew J. Schwab       /s/ Dr. Kush Parmar
      Andrew J. Schwab     Dr. Kush Parmar

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $VOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    10/15/2025$64.00Neutral → Outperform
    Robert W. Baird
    9/24/2025$55.00Hold → Buy
    Stifel
    6/30/2025$3.00Neutral → Buy
    H.C. Wainwright
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    More analyst ratings

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

    BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds from the offering are expected to be $100 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on or about November 12, 2025, subject to customary closing conditions. In addition, Vor Bio has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 s

    11/10/25 9:56:14 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

    BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. In addition, Vor Bio intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Vor Bio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offe

    11/10/25 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

    Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 39 weeks compared with placebo; statistically significant benefits also achieved across all key secondary endpoints Data presented as late-breaking oral presentation at American Society of Nephrology's Kidney Week 2025 BOSTON, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that the primary endpoint was ac

    11/8/25 11:45:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. sold $10,368,938 worth of shares (400,408 units at $25.90) (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    10/30/25 6:40:35 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. sold $6,204,863 worth of shares (221,166 units at $28.06) (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    10/27/25 8:04:07 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. sold $3,433,992 worth of shares (117,050 units at $29.34) (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    10/22/25 7:48:06 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vor Biopharma upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Vor Biopharma from Neutral to Outperform and set a new price target of $64.00

    10/15/25 8:11:51 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Biopharma upgraded by Stifel with a new price target

    Stifel upgraded Vor Biopharma from Hold to Buy and set a new price target of $55.00

    9/24/25 7:54:22 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00

    6/30/25 7:56:45 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    SEC Filings

    View All

    SEC Form 424B5 filed by Vor Biopharma Inc.

    424B5 - Vor Biopharma Inc. (0001817229) (Filer)

    11/10/25 4:26:22 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-3/A filed by Vor Biopharma Inc.

    S-3/A - Vor Biopharma Inc. (0001817229) (Filer)

    11/10/25 4:23:58 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.

    SCHEDULE 13G - Vor Biopharma Inc. (0001817229) (Subject)

    11/7/25 11:13:44 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    1/2/25 7:42:04 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

    BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team. "We are thrilled to welcome Jeremy to Vor Bio," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His deep clinical expertise as a rheumatologist, coupled with his strong track record in industry and as a thought leader in autoimmune and inflammato

    11/3/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h

    9/23/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Financials

    Live finance-specific insights

    View All

    Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

    Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) reduction vs 19.3% on placebo at 24 weeks Sustained efficacy and favorable safety profile through 48 weeks support potential best-in-disease profile in primary Sjögren's disease (pSD) Company evaluating timing of global Phase 3 clinical study in primary Sjögren's diseaseVor Bio to host a conference call on Tuesday, October 28, 2025 at 4:30PM ET BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-sta

    10/14/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

    CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

    5/8/25 8:30:15 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

    Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

    12/9/24 7:30:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:08:06 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care